Studies of the immune response to MIDV-266 have revealed a complex interplay between innate and adaptive immunity. Infected individuals mount a robust inflammatory response, characterized by elevated levels of cytokines and chemokines. Neutralizing antibodies have been detected in convalescent sera, suggesting that humoral immunity plays a role in controlling infection. However, the mechanisms underlying MIDV-266 pathogenesis remain poorly understood, with ongoing research focused on elucidating the viral and host factors contributing to disease severity.